Skip to main content
. 2015 Oct 27;30(Suppl 1):S88–S94. doi: 10.3346/jkms.2015.30.S1.S88

Table 3. Treatment according to the staging of ROP in VLBW infants.

Treatment No. ROP (n=1,323) ROP
Stage 1 (n=235) Stage 2 (n=218) Stage 3 (n=229) Stage 4 (n=4) Total (n=686)
Gestational age (week) 29.8 ± 2.4 27.4 ± 2.2 27.9 ± 2.1 27.4 ± 2.2 26.9 ± 2.2 26.5 ± 2.2
Birth weight (g) 1,197 ± 216 959 ± 244 1,025 ± 241 959 ± 244 912 ± 252 913 ± 252
Length of hospitalization (d) 59 ± 25 83 ± 36 98 ± 34 116 ± 42 154 ± 84 98 ± 38
ROP_treatment (No. %) - 8 (3.4) 41 (18.8) 178 (78.4) 4 (100) 231 (33.7)
 Operation - 6 (2.6) 32 (14.7) 150 (66.1) 4 (100) 192 (28.0)
 Anti-VEGF - 3 (1.3) 15 (6.9) 65 (28.6) 1 (25) 84 (12.2)
 Operation+anti-VEGF - 1 (0.4) 6 (2.8) 37 (16.3) 1 (25) 45 (6.6)

Data are presented as n (%) or mean±standard deviation. ROP, retinopathy of prematurity; VEGF, vascular endothelial growth factor.